-
Periodic hemidiaphragmatic paresis: a puzzling diaphragm Thorax (IF 9.0) Pub Date : 2025-06-03
Miguel Jiménez-Gómez, Carlos Pablo de Fuenmayor-Fernández de la Hoz, Ana Hernández-VothDiaphragmatic dysfunction is an uncommon and often overlooked cause of dyspnoea, particularly when symptoms progress insidiously. We present the case of a 50-year-old man with a history of a bicycle accident, without associated thoracic trauma. A routine chest X-ray revealed an elevated left hemidiaphragm (figure 1A,B), initially presumed to be trauma-related. Despite this finding, the patient remained
-
Smoke and mirrors: uncovering sex differences in COPD Thorax (IF 9.0) Pub Date : 2025-06-03
Georgie May Massen, Hannah WhittakerRecent years have seen an increase in recognition of women’s health and the importance of understanding how disease presentation, progression and management differ by sex and gender. Growing evidence has demonstrated the impact of hormone fluctuations, including puberty and menopause, on health-related outcomes.1 2 Organisations and policies including the European Medicines Agency, the National Institute
-
Performance of volume and diameter thresholds in malignancy prediction of solid nodules in lung cancer screening Thorax (IF 9.0) Pub Date : 2025-06-02
Andrew W Creamer, Carolyn Horst, Ruth Prendecki, Priyam Verghese, Amyn Bhamani, Helen Hall, Sophie Tisi, Jennifer L Dickson, Chuen R Khaw, John McCabe, Tanita Limani, Kylie Gyertson, Anne-Marie Hacker, Jonathan Teague, Laura Farrelly, Shrinkhala Dawadi, Neal Navani, Allan Hackshaw, Anand Devaraj, Arjun Nair, The SUMMIT Consortium, Sam M JanesBackground Prospective validation and comparison of the performance of nodule management protocols is limited. The aim of this study was to examine the performance of size and risk thresholds for assessing malignancy in solid nodules at baseline low-dose CT (LDCT) in a lung cancer screening (LCS) programme. Methods This was an observational study using data from the SUMMIT Study, a prospective longitudinal
-
Comparison of volume-based and diameter-based assessment of solid nodules in lung cancer screening Thorax (IF 9.0) Pub Date : 2025-06-02
Mark M HammerLung cancer screening (LCS) with low-dose CT has been proven to reduce lung cancer-specific mortality in high-risk individuals. However, there has been a lot of concern regarding false-positive scans requiring additional imaging follow-up or even biopsies. Reporting guidelines, such as those developed by the American College of Radiology (ACR Lung-RADS)1 or the British Thoracic Society (BTS),2 aim
-
Randomised, placebo-controlled trial of oral hymecromone in adults with pulmonary hypertension Thorax (IF 9.0) Pub Date : 2025-06-01
Kathryn Czepiel, Nadine Nagy, Tamera Panjalingam, Anissa Kalinowski, Adam R Frymoyer, Harry Karmouty-Quintana, Bo Gu, Haley Hedlin, Gernot Kaber, Sylvie Dobrota Lai, Joelle I Rosser, Paul L Bollyky, Vinicio de Jesus Perez, Roham T ZamanianBackground Pulmonary hypertension (PH) is a progressive cardiopulmonary condition associated with increased morbidity and mortality. The extracellular matrix component hyaluronan (HA) is linked to vascular remodelling and interstitial fibrosis in PH. We hypothesised that inhibition of HA synthesis with hymecromone could serve as a reverse-remodelling therapy in PH. Methods We performed a proof-of-concept
-
Early phase clinical trials in pulmonary hypertension: how small is big enough? Thorax (IF 9.0) Pub Date : 2025-06-01
Steven D NathanIn this issue of Thorax , Czepiel et al report the results of a double-blind randomised controlled trial of an oral agent, hymecromone, in patients with pulmonary hypertension (PH).1 The authors provide a sound biological rationale as to why hyaluronan, a constituent of the extracellular matrix, may have an important role in vascular biology. The agent subjected to study is hymecromone, an inhibitor
-
What is adequate preoxygenation? – Authors' reply Lancet Respir. Med. (IF 38.7) Pub Date : 2025-05-30
Shane George, Tara WilliamsNo Abstract
-
What is adequate preoxygenation? Lancet Respir. Med. (IF 38.7) Pub Date : 2025-05-30
Nirvik Pal, Bryant W TranNo Abstract
-
Extracorporeal cardiopulmonary resuscitation for refractory cardiac arrest Lancet Respir. Med. (IF 38.7) Pub Date : 2025-05-30
Alexander Supady, Jan Bělohlávek, Alain Combes, Alice Hutin, Roberto Lorusso, Graeme MacLaren, Ingrid Magnet, Marcel van de Poll, Susanna Price, Dawid L Staudacher, Fabio Silvio Taccone, Demetri Yannopoulos, Daniel BrodieWhen conventional cardiopulmonary resuscitation (CCPR) cannot restore spontaneous circulation, the initiation of venoarterial extracorporeal membrane oxygenation during refractory cardiac arrest—known as extracorporeal CPR (ECPR)—might restore circulation and adequate tissue oxygenation. ECPR could substantially improve survival with favourable functional recovery. However, the complexity and time-sensitive
-
Lung development genes, adult lung function and cardiovascular comorbidities Thorax (IF 9.0) Pub Date : 2025-05-30
Laura Portas, Mohammad Talaei, Charlotte Dean, Nay Aung, Matthew David Hind, Alfred Pozarickij, Robin G Walters, China Kadoorie Biobank Collaborative Group, Peter GJ Burney, Steffen Petersen, Cosetta Minelli, Seif O ShaheenBackground The association between lower adult lung function and increased cardiovascular comorbidity has not been adequately explained. We investigated whether shared developmental signalling pathways, critical to lung development and repair, could partly explain it. Methods In UK Biobank (UKB), we performed pairwise colocalisation analysis of variants in 55 lung development genes associated with
-
Smart steps forward: the role of wearables in long-term rehabilitation after lung transplantation Thorax (IF 9.0) Pub Date : 2025-05-30
Miguel Jiménez-Gómez, Javier Sayas CatalanPhysical inactivity is a modifiable and widespread risk factor in chronic disease populations, including those with obstructive pulmonary disease and recipients of lung transplantation (LT). While LT restores respiratory function, full physical recovery remains elusive. Muscle weakness and reduced exercise tolerance are common and often worsened by immunosuppressive therapies, immobility and nutritional
-
Effect of elexacaftor/tezacaftor/ivacaftor on systemic inflammation in cystic fibrosis Thorax (IF 9.0) Pub Date : 2025-05-30
Rosemary E Maher, Urszula M Cytlak-Chaudhuri, Saad Aleem, Peter Barry, Daniel Paul Brice, Eva Caamaño Gutiérrez, Kimberley Driver, Edward Emmott, Alexander Rothwell, Emily Smith, Mark Travis, Dave Lee, Paul Stephen McNamara, Ian Waller, Jaclyn Ann Smith, Andrew Jones, Robert W LordBackground Despite significant clinical improvements, there is evidence of persisting airway inflammation in people with cystic fibrosis (CF) established on elexacaftor/tezacaftor/ivacaftor (ETI) therapy. As CF is a multi-system disease, systemic immune profiles can reflect local inflammation within the lungs and other organs. Understanding systemic inflammation after ETI therapy may reveal important
-
Combining tuberculin skin test with follow-on interferon gamma release assay markedly improves screening of household contacts Thorax (IF 9.0) Pub Date : 2025-05-30
Chi Kuen Chan, Chi Chiu Leung, Shan Shan Huang, Shuk Nor Maria Lee, Lai Bun TaiIntroduction In Hong Kong, tuberculin skin test (TST) with a 15 mm cut-off was used at 0 and 3 months for contact screening, but half of future tuberculosis cases might be missed. Follow-on interferon-gamma release assay (IGRA) was added for those with tuberculin reaction of 5–14 mm in a pilot programme. Methods This was a prospective cohort study. All household contacts of smear-positive tuberculosis
-
1-year physical activity coaching programme in lung transplant recipients: an RCT Thorax (IF 9.0) Pub Date : 2025-05-30
Sofie Breuls, Astrid Blondeel, Marieke Wuyts, Geert M Verleden, Robin Vos, Wim Janssens, Thierry Troosters, Heleen DemeyerIntroduction Most lung transplant (LTX) recipients do not meet physical activity (PA) guidelines. Interventions are needed as long-term inactivity is related to morbidity and mortality. We investigated the effect of a telecoaching programme on objectively measured PA in LTX recipients. Methods Inactive patients (<7500 steps/day, n=90) were randomised into a light or intensive version of a 1-year PA
-
Adapting for the future: what can we learn from REMAP-CAP and COVID-19 pandemic trials? Thorax (IF 9.0) Pub Date : 2025-05-30
Heather L Clark, Daniel Clark FilesIn this issue of Thorax , the REMAP-CAP investigators publish the final results from the COVID-19 Immune Modulation Therapy Domain for COVID-19 of Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community-Acquired Pneumonia (REMAP-CAP).1 REMAP-CAP is an international, adaptive, platform trial focused on hospitalised patients with pneumonia. At the outset of the COVID-19 pandemic in
-
Arrival of biosimilars in respiratory medicine: towards improved access to biologics for patients Lancet Respir. Med. (IF 38.7) Pub Date : 2025-05-28
Job F M van Boven, Fernando de Mora, Giorgio W Canonica, Peter G M Mol, Arnold G VultoNo Abstract
-
Persisting CD19.CAR-T cells in combination with nintedanib: clinical response in a patient with systemic sclerosis-associated pulmonary fibrosis after 2 years Lancet Respir. Med. (IF 38.7) Pub Date : 2025-05-28
Wolfgang Merkt, Manuel Röhrich, Eleni Mavriopoulou, Ayla Nadja Stütz, Jörg H W Distler, Anita Schmitt, Markus Polke, Claus Peter Heußel, Michael Schmitt, Hanns-Martin LorenzSection snippets ContributorsWM and H-ML oversaw the project; MR and EM were involved with FAPI-PET/CT, including graphs; CPH was involved with CT-imaging, including graphs; WM, H-ML, AS, JHWD, and MP were responsible for clinical data interpretation; WM, MS, AS, H-ML, and MP cared for the patient; WM was responsible for data handling; WM and ANS wrote the manuscript; and all authors critically reviewed
-
Prostacyclin for Patients with Septic Shock: Promise, Progress, and Perspective. Am. J. Respir. Crit. Care Med. (IF 19.3) Pub Date : 2025-05-29
Anders Perner,Jakob Stensballe -
From Blood to Vessel: Lipid Ratios in Pulmonary Hypertension. Am. J. Respir. Crit. Care Med. (IF 19.3) Pub Date : 2025-05-29
Lars Harbaum,Hans Klose,Martin R Wilkins -
When There's Smoke, Look for the Fire - The Complex Interplay Between Delirium and Dementia. Am. J. Respir. Crit. Care Med. (IF 19.3) Pub Date : 2025-05-29
Lisa Burry,Yahya Shehabi -
Using the 2024 NASEM Definition of Long COVID: Implications for Pulmonary and Critical Care Medicine. Am. J. Respir. Crit. Care Med. (IF 19.3) Pub Date : 2025-05-29
Jerry A Krishnan,Bin Cao,Sanjay H Chotirmall,E Wesley Ely,Peter Openshaw,Nicolas Roche,Grant Waterer -
-
Artificial intelligence-powered interpretation of lung function in interstitial lung diseases Thorax (IF 9.0) Pub Date : 2025-05-27
Semra BilaçeroğluArtificial intelligence (AI) is a branch of computer science developed in the 1950s to imitate the human ability for solving complex problems. Currently, it is widely applied in various fields of medicine for diagnostic support, assistance with medical practice and drug discovery. After entering respiratory medicine two decades ago, AI has been used in this field to support in making diagnoses and
-
Lung cancer risk assessment by prediction model: a global perspective Thorax (IF 9.0) Pub Date : 2025-05-27
Longyao Zhang, Xiang Wang, Qiuyuan Chen, Mengsheng Zhao, Can Ju, David C Christiani, Feng Chen, Ruyang Zhang, Yongyue WeiBackground Numerous lung cancer risk prediction models have been developed and validated worldwide. It is imperative to offer a comprehensive overview and comparative analysis of their performances. Methods We conducted an extensive literature search to identify studies developing and/or validating lung cancer risk prediction models. Then we summarised and compared the external performance of these
-
Addressing heterogeneous treatment effects in acute care syndromes: principles and practical considerations Thorax (IF 9.0) Pub Date : 2025-05-27
Fernando G Zampieri, Sean M Bagshaw, Alexandre B CavalcantiBackground Critical care medicine has historically relied on syndromic diagnoses such as sepsis, acute respiratory distress syndrome (ARDS) and acute kidney injury to guide research and treatment. While this approach has advanced clinical practice, the growing recognition of patient heterogeneity presents significant challenges for treatment optimisation and trial interpretation. Understanding heterogeneous
-
129Xe-MRI ventilation and acinar abnormalities highlight the significance of spirometric dysanapsis: findings from the NOVELTY ADPro UK substudy Thorax (IF 9.0) Pub Date : 2025-05-27
Laurie J Smith, Helen Marshall, Demi Jakymelen, Alberto Biancardi, Guilhem J Collier, Ho-Fung Chan, Paul J C Hughes, Martin L Brook, Josh R Astley, Ryan Munro, Smitha Rajaram, Andrew J Swift, David Capener, Jody Bray, Jimmy E Ball, Oliver Rodgers, Bilal A Tahir, Madhwesha Rao, Graham Norquay, Nicholas D Weatherley, Leanne Armstrong, Latife Hardaker, Alberto Papi, Rod Hughes, Jim M WildRationale Airways dysanapsis is defined by CT or spirometry as a mismatch between the size of the airways and lung volume and is associated with increased risk of developing chronic obstructive pulmonary disease (COPD). Lung disease in participants with dysanapsis and a label of asthma and/or COPD remains poorly understood. Methods In participants with asthma and/or COPD, we used 129Xe-MRI to assess
-
Epithelial damage and ageing: the perfect storm Thorax (IF 9.0) Pub Date : 2025-05-27
Richard J Hewitt, Laurence Pearmain, Elisavet Lyka, Jennifer DickensBackground Idiopathic pulmonary fibrosis (IPF) is a progressive disease of lung parenchymal scarring that is triggered by repeated microinjury to a vulnerable alveolar epithelium. It is increasingly recognised that cellular ageing, whether physiological or accelerated due to telomere dysfunction, renders the epithelium less able to cope with injury and triggers changes in epithelial behaviour that
-
Smoking gun: when COPD therapies fail current smokers Thorax (IF 9.0) Pub Date : 2025-05-27
Elsa Ben Hamou-Kuijpers, Simon CouillardChronic obstructive pulmonary disease (COPD) is mainly treated with bronchodilators (long-acting beta-agonists (LABA) and/or long-acting muscarinic antagonists (LAMA)) to reduce symptoms and exacerbations. Inhaled corticosteroids (ICS) are also frequently used, more recently in the form of single inhaler triple therapy (SITT).1–3 There are numerous established adverse effects of ICS (pneumonia, mycobacterial
-
ERJ Podcast May 2025: Efficacy and safety of the activin signalling inhibitor sotatercept. Eur. Respir. J. (IF 16.6) Pub Date : 2025-05-27
-
Impact of Myanmar's earthquake on respiratory health Lancet Respir. Med. (IF 38.7) Pub Date : 2025-05-23
Sanjeet BagcchiNo Abstract
-
Ultrathin bronchoscopy with radial endobronchial ultrasound and rapid on-site evaluation for the diagnosis of peripheral pulmonary lesions: a multicentre randomized controlled factorial trial. Chest (IF 9.5) Pub Date : 2025-05-24
Erik Vakil,Marc Fortin,Anne V Gonzalez,Laïla Samy,Alex C Chee,Elaine Dumoulin,Marie Dvorakova,Christopher A Hergott,Moosa Khalil,Noël Lampron,Paul MacEachern,Simon Martel,Benjamin Shieh,Mathieu Simon,Thibaud Soumagne,Tatjana Terzic,Alain TremblayBACKGROUND The routine use of computed tomography and lung cancer screening has increased the incidence of peripheral pulmonary lesions (PPLs). Sampling may be needed for some nodules. Many new technologies are available to improve the diagnostic performance of bronchoscopy for the sampling of PPLs, but few comparative trials exist. The objective of this study was to compare the diagnostic performance
-
Pulmonary Rehabilitation Referral Practice Patterns across Lung Transplant Centers in the US: A Multi-Center Survey-Based Study. Chest (IF 9.5) Pub Date : 2025-05-24
Juan D Deleija,Sadia Z Shah,Jamie Felzer,Chris Garvey,Thomas W DeCato,Kelly Pennington,Sameep Sehgal,Cassie Kennedy,Anupam KumarBACKGROUND Functional status and frailty are important considerations in lung transplant (LT) candidacy due to the potential impact on post LT outcomes. Once listed, waitlist duration can be unpredictable, and preservation of functional capacity is thus critical to prevent deterioration in conditioning. Pulmonary rehabilitation (PR) has been deemed to be a cornerstone of management of chronic lung
-
To Make a Self: Exploring and Supporting Professional Identity Formation and Resilience of Intensivists through Humanities. Chest (IF 9.5) Pub Date : 2025-05-23
Briseida Mema,Andrew Helmers,Catherine Proulx,Laura E NavneBACKGROUND Becoming a clinician requires not only the accumulation of medical knowledge but also the development of a professional identity. The humanities may illuminate how professional and personal experiences shape identity, support meaning-making, and foster resilience through reflection and creative expression. RESEARCH QUESTION What transformative experiences disrupt the professional identity
-
HOW I DO IT Selecting An Inhaled Delivery System in COPD. Chest (IF 9.5) Pub Date : 2025-05-23
Donald A Mahler,David M G HalpinChallenges facing health care professionals (HCPs) in selecting an inhaled medication-delivery system for patients with chronic obstructive pulmonary disease (COPD) include: 1. numerous maintenance medications and combinations; 2. at least 22 different handheld inhaler devices; 3. management recommendations focusing mainly on classes of medications; 4. lack of knowledge about available medications/combinations
-
Structure–function–treatment relationships of aerosol deposition in patients with severe asthma Thorax (IF 9.0) Pub Date : 2025-05-22
Omar Usmani, Sylvia VerbanckInhaled aerosols, the cornerstone in the everyday therapeutic management of patients with asthma, target drug directly to their pathophysiological site of action within the lungs. Asthma is a disease of the whole airway tree1; that is, the central and peripheral airways, where the peripheral airways are considered a treatable trait.2 However, the complex architecture of the lungs with varied morphologic
-
Renal dysfunction and outcomes in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: an individual participant data meta-analysis. Eur. Respir. J. (IF 16.6) Pub Date : 2025-05-22
Amber Meservey,Nadine Al-Naamani,Jasleen Minhas,Jason S Fritz,Dina Appleby,Guillaume Baudry,Nicolas Girerd,Rui Feng,Steven M Kawut,Jude MoutchiaBACKGROUND Pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH) cause right ventricular dysfunction with extrapulmonary sequalae including renal dysfunction. We sought to characterize renal dysfunction in PAH and CTEPH and to assess the effect of pulmonary hypertension treatment on renal function. METHODS We performed an individual participant data meta-analysis
-
Impaired IgA Mucosal Immunity Following Lung Transplantation: A Potential Trigger for Bronchiolitis Obliterans Syndrome. Eur. Respir. J. (IF 16.6) Pub Date : 2025-05-22
François M Carlier,Bruno Detry,Jérôme Ambroise,Nicolas Heddebaut,Thomas Planté-Bordeneuve,Aurélie Daumerie,Elisabeth Longchampt,Loïc Falque,Martine Reynaud-Gaubert,Sandrine Hirschi,Jean-François Mornex,Xavier Demant,Adrien Tissot,Jérôme Le Pavec,Vincent Bunel,David Lair,Marina Pretolani,Alexandre Vallée,Charles Pilette,Olivier Brugière,RATIONALE Bronchiolitis obliterans syndrome (BOS) limits long-term survival after lung transplantation (LuTx) and may be triggered by infections. As immunoglobulin (Ig)A is crucial to ensure adequate mucosal immunity, we explored whether IgA-related mucosal immunity is impaired in BOS. METHODS Sixty LuTx recipients from the COLT cohort were retrospectively included. All participants were in stable
-
Sputum metagenomics in bronchiectasis reveals pan-European variation: an EMBARC-BRIDGE study. Eur. Respir. J. (IF 16.6) Pub Date : 2025-05-22
Kai Xian Thng,Pei Yee Tiew,Micheál Mac Aogáin,Jayanth Kumar Narayana,Tavleen Kaur Jaggi,Fransiskus Xaverius Ivan,Morven Shuttleworth,Merete B Long,Hollian Richardson,Holly Lind,Daniela Alferes de Lima Headley,Kara Robertson,Jennifer Pollock,Pieter C Goeminne,Michal Shteinberg,Anthony De Soyza,Stefano Aliberti,Josje Altenburg,Charles S Haworth,Oriol Sibila,Eva Polverino,Michael R Loebinger,Felix C RingshausenBACKGROUND The EMBARC registry shows considerable variation in culturable microbes in sputum between different European countries. The additive role of next generation metagenomic sequencing remains unexplored and association with antimicrobial resistomes unknown. METHODS We prospectively assessed sputum from N=349 individuals recruited into the EMBARC-BRIDGE study with next-generation shotgun metagenomic
-
Comparability, acceptability and longitudinal adherence with digital emPHasis-10 in pulmonary arterial hypertension. Eur. Respir. J. (IF 16.6) Pub Date : 2025-05-22
Joseph Newman,Frances Varian,Felicity Hitchcock,Rebecca Burney,Gregg Harry Rawlings,John Harrington,Ze Ming Goh,Jenna Ablott,David G Kiely,Iain Armstrong,A A Roger Thompson,Jill Carlton,Elin Haf Davies,Alexander Rothman,Mark Toshner -
How do people with COPD walk? A European study on digitally measured real-world gait. Eur. Respir. J. (IF 16.6) Pub Date : 2025-05-22
Laura Delgado-Ortiz,Joren Buekers,Nikolaos Chynkiamis,Heleen Demeyer,Anja Frei,Elena Gimeno-Santos,Clint Hansen,Jeffrey M Hausdorff,Nicholas S Hopkinson,Carl-Philipp Jansen,Anne Kirsten,Sarah Koch,Walter Maetzler,Dimitrios Megaritis,Milo A Puhan,David Singleton,Ioannis Vogiatzis,Henrik Watz,Silvia Del Din,Brian Caulfield,Clemens Becker,Lynn Rochester,Thierry Troosters,Judith Garcia-AymerichThe amount of walking that people with chronic obstructive pulmonary disease (COPD) do is reduced. However, data on their manner of walking (i.e., gait) is still lacking. We characterised real-world gait in COPD by assessing levels and distributions of gait parameters, and comparing them across COPD severity, and with healthy peers.549 people with COPD from seven European sites and 19 healthy older
-
Particulate matter-related ITIH4 deficiency is associated with an emphysema phenotype of chronic obstructive pulmonary disease through JNK-dependent and JNK-independent signaling. Eur. Respir. J. (IF 16.6) Pub Date : 2025-05-22
Sheng-Ming Wu,Kuan-Yuan Chen,Hsiao-Chi Chuang,Shu-Chuan Ho,Cheng-Wei Lin,Chia-Li Han,Wei-Lun Sun,Po-Hao Feng,Shiou-Fu Lin,Yueh-Hsi Chen,Tzu-Tao Chen,Chien-Hua Tseng,Wen-Te Liu,Kang-Yun LeeRATIONALE : Prolonged exposure to airborne particulate matter (PM) is associated with emphysema and chronic obstructive pulmonary disease (COPD); however, the precise underlying mechanism remains unclear. OBJECTIVES In a previous high-throughput screen, we identified inter-alpha-trypsin inhibitor heavy chain 4 (ITIH4) as a biomarker of long-term PM exposure. We hypothesized that ITIH4 is implicated
-
Rehabilitation for persons with long COVID beyond the recovery phase of SARS-CoV-2 infection. Eur. Respir. J. (IF 16.6) Pub Date : 2025-05-22
Milo A Puhan,Kaba Dalla Lana -
Equity in research: a global consensus statement on the urgency of including children in long COVID clinical trials. Eur. Respir. J. (IF 16.6) Pub Date : 2025-05-22
Lael M Yonker,Binita Kane,Etheresia Pretorius,David Putrino,Sammie McFarland,Petter Brodin,Kanecia O Zimmerman,Daniel Munblit,Peter C Rowe,Theo Vos,David Warburton,Terence Stephenson,Danilo Buonsenso, -
Clean air prescriptions: investing in healthy lungs and a healthier future. Eur. Respir. J. (IF 16.6) Pub Date : 2025-05-22
José Luis Castro,Maria Neira,Sarah Rylance,Marit Viktoria Pettersen,Samantha Pegoraro -
Tofacitinib in anti-MDA5-positive dermatomyositis-associated interstitial lung disease: a new standard of care emerges. Eur. Respir. J. (IF 16.6) Pub Date : 2025-05-22
Toyoshi Yanagihara,Reza D Mirza,Martin R J Kolb -
Are systemic corticosteroids needed for all asthma exacerbations? Eur. Respir. J. (IF 16.6) Pub Date : 2025-05-22
William W Busse,Paul M O'Byrne -
British Thoracic Society Clinical Statement on Aspergillus-related chronic lung disease. Thorax (IF 9.0) Pub Date : 2025-05-22
Jeremy Stuart Brown,Darius Armstrong-James,Jonathan Ayling-Smith,Matthijs Backx,Meg Coleman,David Connell,Paddy Dennison,Damian G Downey,Fiona Lynch,Wei Shen Lim,Jenny White,Caroline Baxter -
Aspergillus-related lung disease: a wake-up call to navigate complexity in a neglected condition. Thorax (IF 9.0) Pub Date : 2025-05-22
Anand Shah,Chris Kosmidis -
Sepsis in patients who are immunocompromised: diagnostic challenges and future therapies Lancet Respir. Med. (IF 38.7) Pub Date : 2025-05-20
Stefanie Deinhardt-Emmer, Benjamin G Chousterman, Joerg C Schefold, Stefanie B Flohé, Tomasz Skirecki, Matthijs Kox, Martin S Winkler, Andrea Cossarizza, W Joost Wiersinga, Tom van der Poll, Markus A Weigand, Sara Cajander, Evangelos J Giamarellos-Bourboulis, Gunnar Lachmann, Massimo Girardis, Brendon P Scicluna, Ricard Ferrer, Didier Payen, Sebastian Weis, Antoni Torres, Hjalmar R BoumaSepsis is a life-threatening, dysregulated host response to infection. Immunosuppression is a risk factor for infections and sepsis. However, the specific immune derangements elevating the risk for infections and sepsis remain unclear in the individual patient, raising the question of whether a general state of immunosuppression exists. In this Review, we explore the relationship between immunosuppression
-
Inhaled corticosteroids may be useful in bronchiectasis with peripheral blood eosinophilia Thorax (IF 9.0) Pub Date : 2025-06-01
Cassandra Thompson, Peter G MiddletonBronchiectasis, a clinical syndrome of recurrent cough and sputum production, can be diagnosed when high-resolution CT (HRCT) scans show pathological airway enlargement. Obstructive airway diseases, including asthma and chronic obstructive pulmonary disease (COPD), are diagnosed by the presence of obstructive spirometry with a ratio of forced expiratory volume in 1 s (FEV1) over forced vital capacity
-
You can’t always get what you want: evidence for exacerbation reduction with domiciliary oxygen therapy Thorax (IF 9.0) Pub Date : 2025-06-01
Peter M A CalverleyOn a rather cold summer afternoon 45 years ago, I found myself, a humble research fellow, in a committee room in the University of Birmingham UK surrounded by famous professors and investigators of hypoxaemic lung disease. My chief, the late Professor David Flenley, had been asked by the British Council to lecture in China and had sent me to deputise for him on the writing committee of the Medical
-
Short-term efficacy of inhaled short-acting beta-2-agonists for acute wheeze/asthma symptoms in preschool-aged children: a systematic review and meta-analysis Thorax (IF 9.0) Pub Date : 2025-06-01
Rosa Storgaard Petersen, Henrik Hallas, Nicklas Brustad, Bo ChawesBackground Inhaled short-acting β2-agonists (SABA) is recognised as an effective treatment in adults and older children with asthma, but the effect in young children and infants is still up for debate. We examine the efficacy of inhaled SABA for preschool-aged children presenting with acute wheeze/asthma in this systematic review and meta-analysis. Methods PubMed and Embase were searched through August
-
Use of inhaled corticosteroids in bronchiectasis: data from the European Bronchiectasis Registry (EMBARC) Thorax (IF 9.0) Pub Date : 2025-06-01
Jennifer Pollock, Eva Polverino, Raja Dhar, Katerina Dimakou, Letizia Traversi, Apostolos Bossios, Charles Haworth, Michael R Loebinger, Anthony De Soyza, Montserrat Vendrell, Pierre Regis Burgel, Pontus Mertsch, Melissa Jane McDonnell, Sabina Skgrat, Luis Maiz-Carro, Oriol Sibila, Menno van der Eerden, Paula Kauppi, Adam T Hill, Robert Wilson, Branislava Milenkovic, Rosario Menéndez, Marlene MurrisIntroduction Current bronchiectasis guidelines advise against the use of inhaled corticosteroids (ICS) except in patients with associated asthma, allergic bronchopulmonary aspergillosis (ABPA) and/or chronic obstructive pulmonary disease (COPD). This study aimed to describe the use of ICS in patients with bronchiectasis across Europe. Methods Patients with bronchiectasis were enrolled into the European
-
Clinical presentation and prognosis of acute symptomatic pulmonary embolism in patients with concomitant upper-extremity versus lower-extremity deep vein thrombosis Thorax (IF 9.0) Pub Date : 2025-06-01
Álvaro Dubois-Silva, Behnood Bikdeli, David Jiménez, Cristina Barbagelata-López, Carmen Fernández-Capitán, Andris Skride, Khanh Quoc Pham, José Antonio Porras, Nazaret Pacheco-Gómez, Manuel MonrealBackground The impact of deep vein thrombosis (DVT) location on acute pulmonary embolism (PE) prognosis remains uncertain. Methods Using the Registro Informatizado de Enfermedad TromboEmbólica registry, we assessed 30-day and 90-day outcomes in patients with acute symptomatic PE and concomitant upper-extremity (UEDVT) versus lower-extremity DVT (LEDVT). Cox regression was employed for analysis, and
-
Effects of long-term oxygen therapy on acute exacerbation and hospital burden: the national DISCOVERY study Thorax (IF 9.0) Pub Date : 2025-06-01
Yet Hong Khor, Andreas Palm, Alyson W Wong, Sabina A Guler, Filip Björklund, Zainab Ahmadi, Josefin Sundh, Christopher J Ryerson, Magnus EkströmBackground Long-term oxygen therapy (LTOT) improves survival in patients with chronic severe resting hypoxaemia, but effects on hospitalisation are unknown. This study evaluated the potential impact of starting LTOT on acute exacerbation and hospital burden in patients with chronic obstructive pulmonary disease (COPD), interstitial lung disease (ILD) and pulmonary hypertension (PH). Methods Longitudinal
-
Association between asthma and type 2 diabetes in a Swedish adult population: a register-based cross-sectional study Thorax (IF 9.0) Pub Date : 2025-06-01
Mwenya Mubanga, Tong Gong, Awad I Smew, Amanda Wikström, Emma Caffrey Osvald, Katarina Eeg-Olofsson, Christer Janson, Cecilia Lundholm, Catarina AlmqvistObjective Asthma and type 2 diabetes are two important causes of morbidity globally. We examined both the association of type 2 diabetes with asthma in Swedish adults and the familial co-aggregation of the diseases. Methods We conducted a cross-sectional study of all adults aged 25–85 in Sweden between 2009 and 2013. Asthma and type 2 diabetes status were ascertained from the health registers. Models
-
Adult asthma hospitalisations decreased markedly in Finland and Sweden between 2006 and 2022 Thorax (IF 9.0) Pub Date : 2025-06-01
Juho E Kivistö, Jennifer L P Protudjer, Sandra Ekstrom, Jussi Karjalainen, Heini Huhtala, Lauri Lehtimäki, Inger KullA decreasing trend in asthma hospitalisations among Finnish and Swedish children has been reported. However, possible changes in asthma hospitalisations among adults are incompletely characterised. We aimed to investigate the incidence of adult asthma hospitalisations in Finland and Sweden from 2006 to 2022 using Finland’s National Hospital Discharge Register and Sweden’s National Patient Register
-
Effect of time of day and seasonal variation on bronchodilator responsiveness: the SPIRO-TIMETRY study Thorax (IF 9.0) Pub Date : 2025-06-01
Ben Knox-Brown, Fu Chuen Kon, Karl Peter Sylvester, Akhilesh JhaWe investigated the association between time of day and season of testing on the level of bronchodilator responsiveness in a hospital-based population. We found that per 1-hour increment in the working day, the odds of a positive bronchodilator response decreased by 8%. A similar effect was seen when time of day was dichotomised into morning and afternoon time periods. When stratifying by referral
-
Invasive angiolipoma of the mediastinum and lung Thorax (IF 9.0) Pub Date : 2025-06-01
Ziyin Shang, Yongjie Luo, Xiaoling Kang, Chun Hong, Yuan SiA 12-year-old boy presented with a 1 month history of cough and exertional dyspnoea. Physical examination revealed a heart rate of 106 beats/min, a respiratory rate of 28 breaths/min and an O2 saturation of 90–95%. Bilateral breath sounds were coarse with audible rhonchi. Contrast-enhanced chest CT revealed a large mass in the mediastinum and left lung. The mass encased mediastinal structures and protruded
-
Occlusive primary endobronchial amyloid tumour: a rare case Thorax (IF 9.0) Pub Date : 2025-06-01
Joseph Michael Curran, Daniel Steinfort, Belinda LiuA female aged 69 year never smoker presented with 4 months of non-resolving productive cough and shortness of breath on exertion following mild COVID-19 infection. Her background history was significant for tuberculosis infection in 1996, for which she completed a full course of treatment. An initial CT scan of the chest found bulky left hilar and mediastinal lymphadenopathy with heterogeneous calcification